Impact on 30-d readmissions for cirrhotic patients with ascites after an educational intervention: A pilot study

Table 1 Quality indicators for ascites

Refractory ascites
Diagnostic paracentesis in a timely manner
Aspirated fluid sent for cell count, differential and culture
Management with diuretics and sodium restriction in patients with
normal renal function

Table 2 Baseline characteristics, n (%)

Groups	Control (n = 39)	Intervention (n = 46)	P value
Female	18 (46.2)	19 (41.3)	0.7
Age, yr	51.9 (11.4)	54.9 (10.9)	0.2
Hepatology consult	22 (56.41)	30 (65.22)	0.4
MELD-Na score	25.5 (6.2)	26.1 (7.7)	0.7
Comorbidities
CAD	3 (7.69)	4 (8.7)	0.9
CKD	25 (64.1)	39 (84.78)	0.03
DM	11 (28.21)	17 (36.96)	0.4
HD	11 (28.21)	16 (34.78)	0.5
HIV	3 (7.69)	0 (0)	0.06
PVT	5 (12.82)	6 (13.04)	1
Etiology of cirrhosis			0.3
ETOH	23 (58.97)	21 (45.65)
Hepatitis C	1 (2.56)	5 (10.87)
ETOH/Hep C	3 (7.69)	2 (4.35)
Hepatitis B	3 (7.69)	1 (2.17)
NASH	4 (10.26)	8 (17.39)
Other	5 (12.82)	9 (19.57)

MELD-Na: Model of end-stage liver disease-sodium; CAD: Coronary artery disease; CKD: Chronic kidney disease; DM: Diabetes mellitus; HD: Hemodialysis; HIV: Human immunodeficiency virus; PVT: Portal vein thrombosis; ETOH: Alcohol; NASH: Non-alcoholic steatohepatitis.

Table 3 Adherence to quality care and clinical outcomes, n (%)

Groups	Control (n = 39)	Intervention (n = 46)	P value
Quality care	22 (56.41)	25 (54.35)	0.9
Length of stay, d	8.95 (12.8)	11.1 (10.9)	0.4
Complications	17 (43.59)	21 (45.65)	0.9
30-d readmission	19 (52.78)	14 (35)	0.1
In-hospital mortality	3 (7.69)	6 (13.04)	0.4
30-d mortality	4 (11.11)	3 (7.5)	0.6
Total mortality	12 (30.77)	15 (32.61)	0.9

Table 4 Adjusted relative risk for clinical outcomes related to intervention group

	Intervention [RR (95%CI)]	P value
Length of stay > 6 d	1.10 (0.69, 1.74)	0.1
Complications	0.93 (0.58, 1.50)	0.8
30-d readmission	0.62 (0.39, 1.00)	0.05
30-d mortality	0.95 (0.30, 2.99)	0.7
Total mortality	1.07 (0.54, 2.13)	0.8